Cryoport reports fourth quarter and full year 2023 financial results

Fy 2023 revenue of $233.3 million, in-line with guidance year-over-year, commercial cell & gene therapy revenue rose 33%; biostorage/bioservices revenue increased 45% global clinical trials supported reached a record 675 nashville, tenn., march 12, 2024 /prnewswire/ -- cryoport, inc. (nasdaq: cyrx) ("cryoport"), a global leader in supply chain solutions for cell & gene therapies, today announced financial results for the fourth quarter (q4) and year (fy) ended december 31, 2023.
CYRX Ratings Summary
CYRX Quant Ranking